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Summary
Background Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared 
the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on 
bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from bisphosphonate 
therapy.
Methods This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America, 
Latin America, and Europe. We enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who 
had taken an oral bisphosphonate for at least 3 years before screening and alendronate the year before screening; 
an areal BMD T score of –2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. 
Patients were randomly assigned (1:1) via an interactive voice response system to receive subcutaneous 
romosozumab (210 mg once monthly) or subcutaneous teriparatide (20 μg once daily). The primary endpoint was 
percentage change from baseline in areal BMD by dual-energy x-ray absorptiometry at the total hip through month 
12 (mean of months 6 and 12), which used a linear mixed effects model for repeated measures and represented the 
mean treatment effect at months 6 and 12. All randomised patients with a baseline measurement and at least 
one post-baseline measurement were included in the efficacy analysis. This trial is registered with ClinicalTrials.
gov, number NCT01796301.
Findings Between Jan 31, 2013, and April 29, 2014, 436 patients were randomly assigned to romosozumab (n=218) 
or teriparatide (n=218). 206 patients in the romosozumab group and 209 in the teriparatide group were included in 
the primary efficacy analysis. Through 12 months, the mean percentage change from baseline in total hip areal 
BMD was 2·6% (95% CI 2·2 to 3·0) in the romosozumab group and –0·6% (–1·0 to –0·2) in the teriparatide group; 
difference 3·2% (95% CI 2·7 to 3·8; p<0·0001). The frequency of adverse events was generally balanced between 
treatment groups. The most frequently reported adverse events were nasopharyngitis (28 [13%] of 218 in the 
romosozumab group vs 22 [10%] of 214 in the teriparatide group), hypercalcaemia (two [<1%] vs 22 [10%]), and 
arthralgia (22 [10%] vs 13 [6%]). Serious adverse events were reported in 17 (8%) patients on romosozumab and 
in 23 (11%) on teriparatide; none were judged treatment related. There were six (3%) patients in the 
romosozumab group compared with 12 (6%) in the teriparatide group with adverse events leading to investigational 
product withdrawal.
Interpretation Transition to a bone-forming agent is common practice in patients treated with bisphosphonates, such 
as those who fracture while on therapy. In such patients, romosozumab led to gains in hip BMD that were not 
observed with teriparatide. These data could inform clinical decisions for patients at high risk of fracture.
Funding Amgen, Astellas, and UCB Pharma.
Introduction
Patients with osteoporosis are usually treated with bis­
phosphonates as first­line therapy because of medium to 
high effectiveness, long­term experience, and price con­
siderations. For patients who do not respond sufficiently, 
such as those who have persistently low bone mineral 
density (BMD) or those who develop fractures on therapy, 
switching to a bone­forming agent is common clinical 
practice.
Bone­forming agents are important in the management 
of patients with osteoporosis at high risk for fracture 
because they are associated with large BMD gains that 
can address both the bone mass and microarchitectural 
deficits responsible for the increased fracture risk. 
In practice, the use of bone­forming agents such as 
teriparatide is often reserved for patients with a very high 
fracture risk (eg, two or more prevalent fractures) 
or those who have been previously exposed to 
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bisphosphonate therapy; however, data suggest that the 
clinical benefit of teriparatide might be reduced in 
patients transitioning from bisphosphonates compared 
with bisphosphonate­naive patients. Indeed, the use of 
teriparatide in patients who were previously exposed to 
antiresorptives, such as oral bisphosphonates, results in 
a blunting of BMD gains compared with treatment­naive 
patients, particularly at the hip, with decreases in areal 
BMD seen in the first year.1–5 Thus, transitioning patients 
at high risk for fracture from a bisphosphonate to teri­
paratide poses a clinical challenge.
Romosozumab (AMG 785) is a bone­forming agent 
that inhibits sclerostin with a dual effect on bone, 
increasing bone formation and decreasing bone 
resorption.6,7 In a 12­month, phase 2, placebo­controlled 
study of postmenopausal women with low bone mass 
treated with romosozumab, alendronate, or teriparatide, 
romosozumab treatment significantly increased mean 
areal BMD from baseline (11·3% at the lumbar spine 
and 4·1% at the total hip) and was well tolerated.7 In this 
treatment­naive population, areal BMD gains were 
larger in patients treated with romosozumab than in 
those treated with teriparatide. Additionally, findings 
from a pivotal fracture study in women with 
postmenopausal osteoporosis showed that the rapid and 
large gains in BMD associated with romosozumab 
treatment reduced the risk of new vertebral fractures 
and clinical fractures at 12 months compared with 
placebo.8
Here, we report the results of a phase 3 study comparing 
the effects of romosozumab versus teriparatide treatment 
for 12 months in women with post menopausal osteo­
porosis transitioning from bisphosphonate therapy.
Methods
Study design and participants
STRUCTURE is a phase 3b, randomised, open­label, 
active­controlled, parallel­group trial. The study was done 
at 46 sites (clinical practices, hospitals, and research 
centres) in North America, Latin America, and Europe.
Patients were ambulatory, postmenopausal women 
(aged ≥55 to ≤90 years at randomisation) who had 
received oral bisphosphonate therapy at a dose approved 
for postmenopausal osteoporosis for at least 3 years 
before screening, and alendronate (70 mg weekly or 
equivalent) the year immediately before screening. 
Patients had a history of non­vertebral fracture after age 
50 years or vertebral fracture; osteoporosis as 
documented by an areal BMD T score of –2·5 or lower at 
the total hip, femoral neck, or lumbar spine on dual­
energy x­ray absorptiometry (DXA) scans; and at least 
one hip and at least two vertebrae in the L1–L4 region 
Research in context
Evidence before this study
We searched PubMed for papers in any language published up 
to May 30, 2016 with the terms “bone anabolic”, 
“bisphosphonate”, “osteoporosis”, “romosozumab”, and 
“teriparatide”. We restricted the search to papers published in 
peer-reviewed journals only. We reviewed all publications that 
reported the results of randomised clinical trials and relevant 
preclinical studies. Although randomised controlled trials have 
investigated the effects of sequential bisphosphonate and 
bone-forming osteoporosis therapy, none have addressed the 
sequential use of alendronate and a sclerostin monoclonal 
antibody.
Added value of this study
Bone-forming agents are important for the treatment of 
patients at high risk of fracture because they can improve 
deficits in both mass and microstructure that contribute to 
fracture risk. Teriparatide, a parathyroid hormone analogue, is a 
bone-forming agent, approved for human use by the US Food 
and Drug Administration. Teriparatide is often prescribed to 
patients who have been previously exposed to 
bisphosphonates. However, the use of parathyroid hormone 
therapy after bisphosphonate might have limitations; a 
blunting of the bone-forming effect of teriparatide on bone 
mineral density (BMD) has been reported in women with 
previous bisphosphonate use compared with bisphosphonate-
naive patients. The reduced effect of teriparatide during 
sequential administration is most notable at the hip, where 
losses in areal bone density have been documented in patients 
transitioning from bisphosphonate to teriparatide, particularly 
in the year following transition. Thus, it is important to 
understand the effects of the bone-forming agent 
romosozumab compared with teriparatide on bone density and 
estimated strength in patients with osteoporosis who were 
previously treated with antiresorptive agents, such as 
bisphosphonates, in routine clinical practice. To our knowledge, 
STRUCTURE is the first large, randomised, phase 3 trial to 
directly compare the effects of romosozumab and teriparatide 
on BMD, bone turnover, and estimated bone strength in 
postmenopausal women with osteoporosis who were 
previously treated with oral bisphosphonates. Our findings 
showed that 12 months of treatment with romosozumab in 
patients transitioning from oral bisphosphonate therapy 
resulted in BMD gains and improved estimated hip strength 
compared with teriparatide, and that romosozumab was well 
tolerated in this population.
Implications of all the available evidence
These findings are clinically relevant because many patients are 
considered candidates for bone-forming agents after 
bisphosphonate therapy. Our findings suggest that 
romosozumab might be an effective treatment option for 
patients at increased risk for fracture who are transitioning 
from oral bisphosphonate therapy.
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evaluable by DXA. Patients were excluded from the 
study if they had recently used other agents affecting 
bone metabolism, had a serum 25­hydroxyvitamin D 
concentration of less than 50 nmol/L, or had a history of 
metabolic or bone disease, or other disease or condition 
known to affect bone mass. Full inclusion and exclusion 
criteria are detailed in the summary protocol, which is 
available online. An amendment to the protocol is 
summarised in the appendix (p 2). 
This study was done in accordance with International 
Conference on Harmonization Good Clinical Practice 
guide lines and the principles of the Declaration of 
Helsinki. An independent ethics committee or 
institutional review board at each site approved the 
protocol, informed consent form, and all protocol 
amendments. Patients gave written informed consent 
before any study­specific pro cedures were done.
Randomisation and masking
Within 35 days after screening, eligible patients were 
randomly assigned (1:1) in an open­label manner to 
receive either romosozumab or teriparatide for the 
12­month treatment period (appendix p 5). Randomisation 
was done via a central interactive voice response system 
according to a computer­generated schedule prepared by 
the sponsor before the study. Treatment was open label, 
but investi gators assessing efficacy endpoints were 
masked to treat ment assignment.
Procedures
Romosozumab (Amgen, Thousand Oaks, CA, USA) 
210 mg was supplied by the sponsor in single­use 
prefilled syringes and was given subcutaneously as 
three injections of 70 mg each by a health­care 
professional at clinic visits on day 1 and monthly for a 
total of 12 doses. Teriparatide 20 μg was delivered by a 
pre­assembled commercially available pen device 
(Forteo, USA; Forsteo, Europe); patients self­
administered teriparatide 20 μg subcutaneously daily 
for 12 months. Patients were asked to return all used 
and unused pen devices to facilitate assessment of 
compliance. Throughout the study, all patients were 
provided with calcium (500–1000 mg/day) and vitamin D 
(600–800 IU/day) supplementation. Patients in the 
romosozumab group with a serum 25­hydroxyvitamin D 
concentration of between 50 nmol/L and 100 nmol/L at 
screening received 50 000–60 000 IU vitamin D after 
randomisation, which was optional for patients with 
higher concentrations at screening and for patients in 
the teriparatide group.
Areal BMD was measured by DXA (Lunar, Madison, 
WI, USA, or Hologic, Waltham, MA, USA) at the 
proximal femur and lumbar spine (L1–L4) at baseline 
and at months 6 and 12. Integral, cortical, and trabecular 
volumetric BMD and bone mineral content (BMC) at the 
total hip were measured by quantitative CT at baseline 
and at months 6 and 12 with Medical Image Analysis 
Framework software (MIAF­Femur version 6.2.0; 
University of Erlangen, Germany). The quantitative CT 
analysis9 and details of the segmentation of the hip data 
and precision results10 have been described elsewhere. 
For BMD by DXA and quantitative CT, analysis of the 
scans and quality control of the scanners and individual 
scans were done, masked to treatment assignment, by a 
central facility (Bioclinica, Portland, OR, USA, and 
Hamburg, Germany).
Hip strength for a simulated sideways fall was 
estimated by finite element analysis, with the VirtuOst 
software (ON Diagnostics, Berkeley, CA, USA), which is 
approved by the US Food and Drug Administration for 
identifying patients at high risk of fracture and for 
monitoring treatment. By use of previously described 
methods,11 hip strength was assessed from the 
quantitative CT images obtained at baseline and at 
months 6 and 12, and all image processing and 
assessments for the finite element analysis were done 
masked to treatment assignment (ON Diagnostics, 
Berkeley, CA, USA).
Blood biochemistry and haematology were assessed at 
baseline, day 1, and months 1, 6, and 12. Bone turnover 
markers procollagen type 1 N­terminal propeptide 
(P1NP) and C­telopeptide of type 1 collagen (CTX; 
Quintiles, Marietta, GA, USA) were assessed in fasting 
serum samples obtained at baseline, day 14, and 
months 1, 3, 3+14 days, 6, 6+14 days, 9, and 12. 
Romosozumab immuno genicity (PPD, Richmond, VA, 
USA) was assessed in romosozumab­treated patients at 
day 1 and at months 1, 3, 6, and 12 with a validated 
electro chemiluminescent immuno assay, and samples 
that tested positive for binding antibodies were also 
tested for neutralising antibodies as previously 
described by McClung and colleagues.7 In both 
treatment groups, blood samples were taken before 
administration of the drug.
Data for adverse events and concomitant medications 
were obtained throughout the study. Potential cases of 
osteonecrosis of the jaw and atypical femoral fracture 
were externally adjudicated by independent committees.
Outcomes
The primary endpoint was the percentage change from 
baseline in areal BMD by DXA at the total hip through 
month 12 (mean of months 6 and 12). Secondary 
endpoints were percentage change from baseline in areal 
BMD by DXA at the total hip, femoral neck, and lumbar 
spine at months 6 and 12; percentage change from 
baseline in hip strength estimated by finite element 
analysis at months 6 and 12; and percentage change from 
baseline in cortical and integral volumetric BMD and 
integral volumetric BMC by quantitative CT at the hip at 
months 6 and 12. The percentage change from baseline 
in bone turnover markers (P1NP and CTX) was 
an exploratory endpoint. Other quantitative CT 
measurements (eg, trabecular volu metric BMD, cortical 
For the protocol see https://www.
clinicaltrialsregister.eu/ctr-search/
search?query=20080289
See Online for appendix
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and trabecular volumetric BMC) were also assessed. 
Safety was assessed on the basis of the frequency of 
adverse events, changes from baseline in laboratory 
measurements and vital signs, and the presence of anti­
romosozumab antibodies.
Statistical analysis
A key consideration in power calculations for the study 
was the expected total hip areal BMD changes at 
month 12 with romosozumab and teriparatide. We 
assumed that the mean percentage changes in total hip 
areal BMD by DXA from baseline to month 12 would be 
0·8% (SD 1·5) in the romosozumab group (estimating a 
lower increase than that seen in treatment­naive 
patients7) and –1·2 % (4·5) in the teriparatide group, on 
the basis of findings from previous studies.1–3,12 A sample 
size of 200 patients per group was determined, on 
the basis of a two­sided two­sample t test with 
a 5% significance level, to provide 99% power to detect a 
difference between treatment groups with respect to the 
primary endpoint and about 90% power for the 
comparison of romosozumab with teriparatide with 
respect to the percentage change from baseline in total 
hip, femoral neck, and lumbar spine areal BMD by DXA, 
total hip volumetric BMD by quantitative CT, and cortical 
volumetric BMD by quantitative CT at months 6 and 12, 
assuming an annual 5% dropout rate.
A planned two­step, step­down, fixed­sequential testing 
procedure was used for the primary and key secondary 
efficacy endpoints for the comparison of romosozumab 
with teriparatide for multiplicity adjustment to maintain 
the overall significance level at 0·05, as described in the 
appendix (p 2).
All patients with a baseline measurement and at least 
one post­baseline measurement were included in the 
analyses of primary and secondary efficacy endpoints. 
The analysis of the primary endpoint, the treatment 
difference in the percentage change from baseline in 
DXA BMD at the total hip up to month 12, used a linear 
mixed effects model for repeated measures and 
represented the average treatment effect at months 6 
and 12. The model included main effects for treatment 
group, visit (categorical), baseline serum CTX, baseline 
hip DXA areal BMD value, DXA machine type 
(categorical), and machine type by baseline value 
interaction (to adjust for the effect of machine type on 
baseline DXA areal BMD value) as fixed effects with an 
unstructured within­subject variance­covariance 
structure. Analyses were not adjusted for geo graphical 
region because BMD response would not be expected to 
vary by region; we assessed the primary endpoint by 
region with a repeated measures model to confirm this 
assumption. The denominator degrees of freedom were 
determined by the Kenward­Roger approach. Least­
squares mean of the treatment difference (romo­
sozumab–teriparatide) and the corresponding two­sided 
95% CI are reported. The assumptions of the mixed 
effects model were assessed and there was no evidence 
that the assumptions were violated.
The percentage change from baseline in the secondary 
DXA areal BMD endpoints (including total hip, lumbar 
spine, and femoral neck) at each timepoint of interest 
used the same linear mixed effects model for repeated 
measures as did the analysis of the primary endpoint, 
apart from the addition of the treatment­by­visit inter­
action. The analysis of the percentage change from base­
line in secondary quantitative CT endpoints used the 
same model as the secondary DXA areal BMD endpoints 
model, apart from the replacement of the baseline DXA 
areal BMD by the baseline quantitative CT parameter 
value and the removal of the DXA machine type variable. 
For bone turnover markers, the significance of the treat­
ment difference for the percentage change from baseline 
at each timepoint of interest was assessed with a 
Wilcoxon rank­sum test. Statistical analyses were done 
with SAS version 9.2.
Safety endpoints are summarised descriptively for all 
patients who received at least one dose of investigational 
product. Patients in this subset were analysed according 
to the actual treatment received. This study is registered 
with ClinicalTrials.gov, number NCT01796301.
Role of the funding source
Amgen and UCB Pharma representatives designed 
the study in collaboration with external investigators, 
and Amgen was responsible for study monitoring and 
777 patients assessed for eligibility
436 randomly assigned
341 excluded
306 did not meet inclusion criteria
35 other reasons
218 assigned to teriparatide
18 discontinued study
15 consent withdrawn
3 lost to follow-up
0 death*
200 completed study
209 included in primary efficacy 
analysis†
214 included in safety analysis‡
218 assigned to romosozumab
198 completed study
20 discontinued study
15 consent withdrawn
3 lost to follow-up
1 death
1 other
206 included in primary efficacy
analysis†
218 included in safety analysis‡
Figure 1: Trial profile
*One death occurred 3 days after the end of the study. †Primary efficacy analysis population included all randomly 
assigned patients with a non-missing baseline measurement and at least one post-baseline measurement for the 
endpoint of interest. ‡Safety analysis population included all randomised patients who received at least one dose 
of investigational product. Four patients in the teriparatide group never received teriparatide per the patients’ 
request, so they were excluded from the safety analysis set.
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over sight. Amgen statisticians did the statistical analyses 
according to a prespecified statistical analysis plan. The 
first author (BLL) wrote the initial manuscript draft with 
assistance from professional medical writers who were 
funded by Amgen and UCB Pharma. All authors had full 
access to all the data in the study. The corresponding 
author had final responsibility for the decision to submit 
for publication.
Results
Between Jan 31, 2013, and April 29, 2014, 436 patients 
were randomly assigned to receive romosozumab 
(n=218) or teriparatide (n=218). Of these patients, 
198 (91%) in the romosozumab group and 200 (92%) in 
the teriparatide group completed the study. Reasons for 
discontinuation were similar in the two groups (figure 1).
Baseline demographics and disease characteristics 
were similar in the treatment groups (table 1). Women 
were enrolled from western Europe (209 [48%]), central 
and eastern Europe (116 [27%]), Latin America (79 [18%]), 
and North America (32 [7%]). All patients received oral 
bisphosphonate therapy in the 3 years immediately 
before screening and all except two in the teriparatide 
group received alendronate in the year before screening 
(protocol deviation). Most patients had received alend­
ronate in the 3 years before the study, with a mean 
duration of previous alendronate use of 
5·6 years (SD 3·15; table 1). Baseline serum 
concentrations of P1NP and CTX were low, indicating 
the use of antiresorptive therapy, and were similar in 
the two groups.
206 patients in the romosozumab group and 209 in 
the teriparatide group were included in the primary 
efficacy analysis. The mean percentage change from 
baseline in areal BMD by DXA at the total hip up to 
month 12 (ie, the mean of month 6 and month 12) was 
2·6% (95% CI 2·2 to 3·0) in the romosozumab group 
and –0·6% (–1·0 to –0·2) in the teriparatide group; 
mean difference between groups was 3·2% (95% CI 
2·7 to 3·8; p<0·0001). Similar results were obtained 
in the per­protocol analysis: 2·5% (95% CI 2·1 to 2·9) in 
the romosozumab group and –0·8% (–1·2 to –0·3) in 
the teriparatide group; mean difference between groups 
3·3% (95% CI 2·7 to 3·9; p<0·0001). The mean 
differences between treatment groups were similar 
across geographical regions (data not shown).
For the secondary efficacy endpoints, the mean per­
centage changes from baseline in DXA areal BMD at 
the total hip, femoral neck, and lumbar spine were 
signifi cantly greater in the romosozumab group than in 
the teriparatide group at month 6 and at month 12 
(figure 2; appendix p 3). Significantly greater gains in 
integral and cortical volumetric BMD and volumetric 
BMC at the hip were also noted in the romosozumab 
group than in the teriparatide group at months 6 and 12 
(figure 3; appendix p 3), whereas trabecular volumetric 
BMD increased significantly from baseline in both 
treatment groups (figure 3; appendix p 3). On an 
absolute scale, integral volumetric BMC was unchanged 
with teriparatide; romosozumab treatment resulted in 
signifi cant gains compared with teriparatide, with in­
creases in volumetric BMC roughly twice as high in 
cortical (+290 mg) versus trabecular (+148 mg) com­
partments (appendix p 4).
Greater gains in the percentage change from baseline 
in hip strength (estimated by finite element analysis) 
were seen in the romosozumab group than in the 
teriparatide group at month 6 (2·1% vs –1·0%, res­
pectively) and month 12 (2·5% vs –0·7%, respectively; 
p<0·0001 between treatment groups; figure 4, appendix 
p 3).
Concentrations of the bone formation marker P1NP 
rose rapidly after the first dose in the romosozumab 
group, with an initial increase that was significantly 
greater than in the teriparatide group (figure 5). In the 
romosozumab group, P1NP concentrations peaked in the 
first month and then gradually returned towards baseline 
values during the 12 months of treatment. The bone 
resorption marker CTX declined rapidly after the first 
dose of romosozumab and returned to baseline by 
month 3, with concentrations remaining near base line up 
to month 12. Transient increases in P1NP and reductions 
in CTX were also noted in the romosozumab group when 
Romosozumab (n=218) Teriparatide (n=218)
Age (years) 71·8 (7·4) 71·2 (7·7)
Race
White 191 (88%) 196 (90%)
Other 23 (11%) 18 (8%)
American Indian or Alaska native 4 (2%) 1 (<1%)
Asian 0 2 (1%)
Multiple 0 1 (<1%)
Oral bisphosphonate use in the 3 years before 
screening
218 (100%) 218 (100%)
Alendronate in the year before screening 218 (100%) 216 (99%)
Duration of previous bisphosphonate use (years) 6·2 (2·9) 6·2 (2·9)
Duration of previous alendronate use (years) 5·5 (3·2) 5·8 (3·1)
Alendronate use in the 3 years before the study 192 (88%) 202 (93%)
BMD T score
Total hip –2·27 (0·75) –2·21 (0·72)
Femoral neck –2·49 (0·67) –2·43 (0·66)
Lumbar spine –2·83 (1·10) –2·87 (1·04)
Serum CTX (pmol/L)* 982 (654–1348) 1012 (732–1378)
Serum P1NP (μmol/L)† 0·33 (0·24–0·45) 0·33 (0·27–0·44)
Previous fracture 218 (100%) 217 (<100%)
Total hip cortical volumetric BMD by QCT (mg/cm3) 472·8 (64·3) 475·8 (57·5)
Total hip integral volumetric BMD by QCT (mg/cm3) 194·9 (38·9) 194·5 (34·4)
Hip strength under fall loading conditions (N) 2892 (494) 2923 (506)
Data are mean (SD), n (%), or median (IQR). BMD=bone mineral density. CTX=C-telopeptide of type 1 collagen. 
P1NP=procollagen type 1 N-terminal propeptide. QCT=quantitative CT. *Premenopausal reference range for serum 
CTX 861–3875 pmol/L. †Premenopausal reference range for serum P1NP 0·23–0·82 µmol/L.
Table 1: Baseline characteristics
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concentrations were assessed 2 weeks post dose at 
months 3 and 6 (figure 5). In the teriparatide group, P1NP 
and CTX concentrations increased during the first 
6 months of treatment and either stabilised (P1NP) or 
decreased (CTX) during the course of therapy, and 
remained significantly higher than baseline values for the 
subsequent 6 months of treatment. Concentrations of 
PINP and CTX were significantly higher in patients in 
the teriparatide group than in the romo sozumab group at 
all timepoints measured between months 3 and 12.
432 patients (218 on romosozumab and 214 on 
teriparatide) received at least one dose of investigational 
product and were included in the safety analysis. Overall, 
the percentages of patients reporting adverse events 
were generally balanced between the treatment groups 
(table 2), and the types of adverse events reported were 
those that would be expected in the population studied. 
Six (3%) patients in the romosozumab group and 
12 (6%) patients in the teriparatide group had adverse 
events leading to discontinuation of study therapy. 
Serious adverse events were reported in 17 (8%) patients 
on romosozumab and in 23 (11%) on teriparatide; none 
were judged by the investigator to be treatment related. 
Serious adverse events reported by more than one 
participant in either treatment group were atrial 
fibrillation (two [<1%] patients in the romosozumab 
group) and pneumonia and abdominal pain (each 
reported by two [<1%] patients in the teriparatide group). 
Fractures were reported in 15 patients; seven (3%) had 
seven fractures in the romo sozumab group (femoral 
neck, foot [two], rib [two], sternum, and ulna) and 
eight (4%) had nine fractures in the teriparatide group 
(humerus, foot, forearm, pubis [two], radius [three], and 
tibia). There was one death in each treatment group, 
neither of which was thought to be related to the investi­
gational product.
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Figure 2: Percentage change from baseline in areal bone mineral density at the 
total hip, femoral neck, and lumbar spine by dual energy x-ray absorptiometry
Data are least-squares means and 95% CI. *p<0·05 versus baseline. †p<0·0001 
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Injection­site reactions were reported by 17 (8%) 
patients in the romosozumab group and six (3%) in the 
teriparatide group. Most were mild and none were 
judged serious. One patient discontinued romosozumab 
on study day 180 because of injection­site erythema, 
pruritus, and swelling that was reported as severe and 
judged related to romosozumab by the investigator. 
Three (1%) non­serious adverse events of hypocalcaemia 
were reported in the romosozumab group, two of which 
were asymptomatic (detected only biochemically) and 
one in association with complaints of constipation and 
asthenia after the second dose of romosozumab; 
six other patients were reported to have mild decreases 
in calcium detected via laboratory assessments (grade 1 
abnor malities defined as below the normal reference 
range but no lower than 2·0 mmol/L), which were not 
reported as adverse events. In the teriparatide group, 
there were no reports of hypocalcaemia and 22 (10%) 
patients had reports of hypercalcaemia, which were 
reported as grade 1 (mild) in severity. No cases of 
osteonecrosis of the jaw or atypical femoral fracture 
were reported in either group.
All patients in the romosozumab group tested negative 
for pre­existing antibodies against romosozumab. Of the 
210 patients with post­baseline results, 37 (17%) were 
positive for binding antibodies post baseline at least at 
one visit; 16 (43%) of these cases were transient (ie, 
results were negative at the last on­study determination). 
No neutralising antibodies were detected during the 
12­month study period. The presence of antibodies did 
not seem to affect the efficacy or safety of romosozumab 
(data not shown).
Discussion
In women transitioning from bisphosphonate therapy, 
romosozumab treatment significantly increased areal 
BMD by DXA at the hip and spine compared with teri­
paratide in 1 year of therapy. At the hip, the gains in areal 
BMD remained significant despite previous use of bis­
phosphonate, which is known to result in decreased 
bone turnover; at the spine, the gains with romosozumab 
approached those previously reported in treatment­naive 
patients.7,8 Although a small study, romosozumab therapy 
was overall well tolerated in this patient population and 
no new safety findings were seen.
In this high­risk population, areal BMD at the hip 
declined at 6 months with teriparatide, in accordance 
with findings from previous studies.2,3 Quantitative CT 
results extended the hip DXA areal BMD results and 
provided insight into the compartment changes seen 
with romosozumab and teriparatide at this anatomical 
site. The changes in the cortical compartment with 
each treatment are of interest for two reasons. First, 
there are directionally opposed changes (ie, increases 
with romosozumab and decreases with teriparatide), 
which mirror the bone­forming effect of romosozumab 
on the cortex and a catabolic effect of teriparatide, 
which is thought to be a result of increased cortical 
porosity.13–16 Second, although the percentage changes 
in volumetric BMD suggest greater change in the 
trabecular versus cortical compartment, assessment of 
the absolute changes in volumetric BMC shows that the 
contributions to the integral changes in terms of added 
or subtracted bone matrix are larger from the cortical 
versus trabecular compartment.
These changes translated into estimated hip strength 
alterations, which showed declines with teriparatide 
early in treatment and significant gains with 
romosozumab from baseline and over teriparatide at 
month 6 and continuing at month 12. The finite 
element analysis technique uses engineering 
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computational mechanics principles to simulate a 
virtual stress test, in which a patient­specific model of 
the proximal femur is virtually loaded to its failure 
point under forces typical of a sideways fall. Taken 
together, these results suggest that, despite a large 
percentage increase in trabecular BMD with teri­
paratide treatment, the concomitant decrease in cortical 
BMD was sufficiently large that no significant gain in 
hip strength from baseline was seen during the 
12 months after treatment initiation.
The reasons for the larger gains in BMD and estimated 
strength with romosozumab might relate to its mech­
anism of action, because romosozumab has a dual effect, 
increasing bone formation and decreasing bone re­
sorption.7 In the setting of transition from bispho­
sphonates, P1NP concentrations increased early with 
romo sozumab, peaking at 2 weeks and falling back 
towards baseline during the 12­month treatment period, 
remaining higher than baseline concentrations at 
month 12. Serum CTX declined early with romosozumab 
and rose back to baseline values by month 3. Overall, this 
pattern is similar to that seen in patients not previously 
exposed to other osteoporosis treatment,7,8 although it 
also might indicate some offset of the antiresorptive 
therapy with overlying effects of romosozumab treatment 
to prevent escalations in bone resorption expected to 
occur after discontinuation of bisphosphonates. The 
larger increase in density and mass, denoting a larger 
bone­forming net effect with romosozumab, arose in the 
context of a smaller rise in P1NP with romosozumab than 
with teriparatide. If P1NP is a marker of the amount of 
new bone being formed, the profile of bone turnover 
markers suggests that the pro­remodelling effect of 
teriparatide to increase bone resorption is likely to partly 
counteract the apparently larger bone formation response. 
Indeed, the increase in remodelling associated with 
teriparatide might be responsible for the deterioration of 
cortical mass seen with teriparatide, as shown by the 
cortical volumetric BMD effects detected in this study.
In primate studies, romosozumab increased bone 
formation predominantly on modelling surfaces,17 thus 
not depending on ongoing remodelling. If the same 
process occurred in people, it could account for the 
significant improvement in bone mass after treatment 
in patients transitioning from a bisphosphonate; by 
contrast, teriparatide, which improves bone formation 
mainly on remodelling surfaces, might have had less of 
a bone accretion action in patients previously treated 
with a bisphosphonate because of less continuous 
remodelling, as shown in this study. A consequence of 
these differences is an increased improvement in BMC, 
BMD, and estimated bone strength, which is desirable 
for patients at risk for fracture. These data are clinically 
important because bone­forming agents in practice are 
commonly used after a patient has received a 
bisphosphonate and had a fracture.
A limitation of this study was the open­label study 
design, which was necessary because of the inability to 
mask the teriparatide pen; however, although the 
treatment assignments were open label, the efficacy 
endpoints were objective measurements and assessed by 
investigators who were masked to treatment allocation. 
Also, this study was not powered to assess the difference 
in fracture incidence between treatment groups, and 
fracture events were not adjudicated or confirmed, 
although finite element analysis showed significant 
gains in strength from baseline. Another limitation 
derives from our not being able to measure any changes 
in the degree of mineralisation. Ettinger and colleagues1 
proposed that early declines in areal BMD and volumetric 
BMD seen with teriparatide could result from the 
replacement of highly mineralised bone with less 
mineralised bone, which would become more 
mineralised over time. However, recent work suggests 
that the bone mineralisation density distribution does 
not differ in biopsy samples obtained at 6 months and 
24 months in patients given teriparatide.18 Although our 
study could not distinguish between highly mineralised 
bone with some porosity versus less mineralised bone 
with less porosity, the finite element­based measurements 
of estimated strength and the associated biomechanics 
depend only on the net amount of mineral in the bone 
tissue. Thus, our simulations suggest that, irrespective of 
the exact cause of the decrease in BMD in the teriparatide 
group, overall bone strength was not increased over the 
course of 12 months.
Finally, because the duration of the study was 
12 months, and teriparatide is approved for up to 
Romosozumab 
(n=218)
Teriparatide 
(n=214)
All adverse events 164 (75%) 148 (69%)
Adverse events
Nasopharyngitis* 28 (13%) 22 (10%)
Arthralgia* 22 (10%) 13 (6%)
Hypercalcaemia* 2 (<1%) 22 (10%)
Injection-site reaction† 17 (8%) 6 (3%)
Hypocalcaemia‡ 3 (1%) 0
Serious adverse events 17 (8%) 23 (11%)
Leading to discontinuation of 
investigational product§
6 (3%) 12 (6%)
Death¶ 1 (<1%) 1 (<1%)
Data are number of patients (%). Denominator is number of patients who 
received at least one dose of investigational product. *Events reported as 10% or 
higher in either treatment group; †Reported as different types of injection-site 
reactions with the most frequent as injection-site pain in the romosozumab 
group. ‡Includes events reported as hypocalcaemia and decreased blood calcium 
concentration. §Adverse events leading to study discontinuation in each 
treatment group were single event types with no particular pattern. 
¶There were two deaths during the trial, unrelated to investigational product; 
one participant with leukaemia in the romosozumab group had a haemorrhage 
and one participant in the teriparatide group had a gastrointestinal 
haemorrhage.
Table 2: Adverse events
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24 months of treatment, our results cannot address 
whether a longer duration of teriparatide treatment 
would have resulted in increased mass and strength over 
a longer exposure term. However, in an 18­month study 
of teriparatide­treated patients who had previously been 
on alendronate,1 mean BMD gains at the total hip 
remained at or below baseline up to month 12, with 
mean gains from baseline of 0·3% at month 18. Notably, 
if the reason to transition a patient from a bisphosphonate 
to a bone­forming agent is to achieve an increase in 
strength to reduce fracture risk, the first year of therapy 
is of clinical relevance. Indeed, it is well documented that 
after a fracture, the risk of a subsequent fracture is 
highest in the next year,19 and other clinical characteristics 
of patients have been identified as putting patients at 
high risk for fracture over a 1­year time horizon.20 Such 
patients at high risk for fracture over the near term might 
particularly benefit from a treatment that improves bone 
strength during this period.
Strengths of this study include the various comple­
mentary imaging modalities used to assess the effects of 
romosozumab treatment, which showed consistent and 
complementary results. The data obtained by finite 
element analysis provided a mechanistic basis for inter­
preting the noted changes in BMD in terms of more 
clinically relevant biomechanical outcomes—namely, 
the estimated strength of the proximal femur under 
typical loading conditions associated with a sideways 
fall. Finally, the analyses in this study controlled for 
baseline variables.
Our findings showed that in patients at high 
risk for fracture transitioning from bisphosphonates, 
romosozumab increased hip and spine BMD and 
estimated hip strength compared with teriparatide 
through a dual effect, increasing bone formation and 
decreasing bone resorption. Integral BMD at the hip and 
estimated hip strength declined with teriparatide use at 
6 months in this population. These results suggest that 
romosozumab might offer a unique benefit to patients 
with post menopausal osteoporosis who are transitioning 
from bis phosphonate therapy.
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